Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV-2 antisera cross-neutralize HIV-1.

R A Weiss1, P R Clapham, J N Weber

  • 1Chester Beatty Laboratories, Institute of Cancer Research, London, UK.

AIDS (London, England)
|April 1, 1988
PubMed
Summary

Antibodies targeting HIV-2 can neutralize HIV-1, but HIV-1 antibodies do not neutralize HIV-2. HIV-2 antigens show promise for developing effective AIDS vaccines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Whole-genome association study of antibody response to Epstein-Barr virus in an African population: a pilot.

Global health, epidemiology and genomics·2018
Same author

Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals.

Philosophical transactions of the Royal Society of London. Series B, Biological sciences·2015
Same author

Lorentz force in water: evidence that hydronium cyclotron resonance enhances polymorphism.

Electromagnetic biology and medicine·2014
Same author

Efficacy and safety of Buxus sempervirens L. preparations (SPV(30)) in HIV-infected asymptomatic patients: a multicentre, randomized, double-blind, placebo-controlled trial.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2012
Same author

Antibodies against lytic and latent Kaposi's sarcoma-associated herpes virus antigens and lymphoma in the European EpiLymph case-control study.

British journal of cancer·2011
Same author

Oxidative stress in critical care medicine.

International journal of clinical practice·2010

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Human immunodeficiency virus (HIV) exists as two distinct species, HIV-1 and HIV-2.
  • Understanding the cross-neutralization between HIV-1 and HIV-2 is crucial for vaccine development.

Purpose of the Study:

  • To compare the neutralization properties of HIV-2 isolates against HIV-1 strains.
  • To investigate the potential of HIV-2 antigens for broad AIDS vaccine development.

Main Methods:

  • Examined neutralization properties of three HIV-2 isolates.
  • Compared these isolates with four diverse HIV-1 strains using human sera.
  • Assessed cross-neutralization capabilities of antibodies specific to each virus type.

Main Results:

Related Experiment Videos

  • Human sera with HIV-2 antibodies demonstrated cross-neutralization against HIV-1.
  • HIV-1 specific sera showed group-specific activity but no neutralizing effect on HIV-2.
  • Asymmetry in cross-neutralization was observed, with HIV-2 antibodies being more broadly effective.

Conclusions:

  • HIV-2 specific antibodies possess cross-neutralizing activity against HIV-1.
  • HIV-1 specific antibodies do not neutralize HIV-2.
  • HIV-2 antigens represent a promising strategy for developing broadly cross-protective AIDS vaccines.